To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL

Start Date13 Aug 2033

Sponsor / Collaborator-

NCT07294755

/ Not yet recruitingNot ApplicableIIT

The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery

the investigators hereby invite participants to participate in a study entitled "The Impact of Intrapleural Block via Thoracoscopic Surgery on Postoperative Pain Caused by Drainage Tubes". This study is an extension of hospital's major clinical research project: "Efficacy and Safety of Perioperative Intrapleural Block with Local Anesthetics for Acute Postoperative Pain in Adult Thoracic and Pulmonary Surgery: A Prospective, Multicenter, Randomized, Open-Label, Positive Parallel-Controlled, Pragmatic Clinical Trial".During breathing and position changes, the postoperative closed thoracic drainage tube continuously rubs against the pleura, causing severe acute pain in patients. This study hypothesizes that analgesia via a single postoperative spray of local anesthetics into the pleural space is effective, and aims pleural space is effective, and aims to investigate whether a single spray of different local anesthetics can alleviate early acute pain caused by postoperative closed thoracic drainage.
This is a pragmatic randomized controlled study. participants have a 1/3 chance of being randomly assigned to Trial Group A, a 1/3 chance to Trial Group B, and a 1/3 chance to the Control Group. If assigned to Trial Group A, participants will receive an intrapleural block with ropivacaine hydrochloride injection; if assigned to Trial Group B, the intrapleural block will contain both ropivacaine hydrochloride injection and tetracaine hydrochloride injection; if assigned to the Control Group, participants will undergo an intrapleural block without any active medications. All three intrapleural block regimens are fully compatible with the overall disease diagnosis and treatment plan and will not exert any differential impact on participants' subsequent treatment. Additionally, participants' other medical procedures and related costs will not be affected in any way.
Before surgery, as well as at 2, 4, 6, 8, 24, 48 and72 hours after surgery, physicians will conduct follow-up assessments. Participants will also need to complete corresponding follow-up questionnaires under the guidance of doctors. These assessments and questionnaires aim to comprehensively evaluate the analgesic efficacy of the medications, the incidence of postoperative depression, anxiety, cognitive impairment, sleep disturbances, delirium, and adverse reactions, while collecting relevant data. No additional fees will be charged for this process.
Participation in this study is entirely voluntary. Participants may refuse to participate or withdraw from the study at any time during the process without providing any reason. This decision will not affect participants' future medical treatment.
If participants decide to withdraw from the study, please notify participants' research physician in advance. To ensure participants' safety, participants may be required to undergo relevant examinations, which are beneficial for protecting participants' health.
If participants decide to participate in this study, participants' participation and personal data collected during the study will be kept strictly confidential. Physicians in charge of the study and other researchers will use participants' medical information for research purposes only. Participants medical records will be accessible exclusively to the research team. Participants identity will remain anonymous, and only the research physicians and members of the research team will have access to participants' assigned study ID.

Start Date20 Apr 2026

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT07449468

/ Not yet recruitingNot ApplicableIIT

Effect of Pericapsular Nerve Group (PENG) Block Added to Spinal Anesthesia on Postoperative Delirium in Older Adults Undergoing Primary Total Hip Arthroplasty: A Prospective, Randomized, Assessor-Blinded Controlled Trial

Postoperative delirium is a common and serious complication in older adults undergoing total hip arthroplasty, associated with prolonged hospitalization, increased morbidity, delayed rehabilitation, and long-term cognitive decline. Modifiable perioperative risk factors include uncontrolled postoperative pain, opioid consumption, impaired early mobilization, and systemic inflammatory response.
The Pericapsular Nerve Group (PENG) block is a regional anesthesia technique targeting the sensory innervation of the anterior hip capsule and may provide effective analgesia while preserving motor function. Improved pain control and opioid reduction may decrease the incidence of postoperative delirium.
This prospective, randomized, parallel-group controlled trial aims to evaluate whether the addition of ultrasound-guided PENG block to spinal anesthesia reduces the incidence of postoperative delirium within 72 hours after primary total hip arthroplasty in patients aged 65 years or older. Delirium will be assessed using the Confusion Assessment Method (CAM) by blinded outcome assessors.
Secondary outcomes include postoperative opioid consumption, pain intensity (NRS), time to first rescue opioid, postoperative nausea and vomiting, time to mobilization, block-related adverse events, and perioperative inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio).
The study will enroll 144 patients randomized 1:1 to spinal anesthesia alone or spinal anesthesia plus PENG block.

Start Date01 Apr 2026

Sponsor / Collaborator

Poznan University of Medical Science

100 Clinical Results associated with Ropivacaine Hydrochloride

100 Translational Medicine associated with Ropivacaine Hydrochloride

100 Patents (Medical) associated with Ropivacaine Hydrochloride

2,274

Literatures (Medical) associated with Ropivacaine Hydrochloride

01 Mar 2026·ANESTHESIA AND ANALGESIA

Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial

Article

Author: Fenten, Maaike G.E. ; Vissers, Kris C.P. ; van Hooff, Miranda L. ; Rood, Akkie ; van Boekel, Regina L.M. ; van de Wijgert, Ilse H.

BACKGROUND::

Postoperative pain after lumbar spine surgery is often severe, necessitating multimodal analgesic regimens that include opioids. Locoregional anesthesia, such as the Erector Spinae Plane Block (ESPB), may be effective in reducing postoperative pain and opioid use. This study evaluated the effect of bilateral ESPB on early postoperative pain and opioid use after lumbar spinal fusion surgery.

METHODS::

A single-center, randomized, blinded, placebo-controlled trial included 76 patients undergoing elective lumbar spinal fusion. Participants received either bilateral ESPB with ropivacaine or placebo (normal saline) after surgery. The primary outcome was pain intensity 1-hour postanesthesia, measured using the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption in the first 12 hours, time to first opioid use, quality of recovery, and pain intensity and opioid use at 30 days. Statistical significance was set at P < .05.

RESULTS::

The mean NRS 1-hour postanesthesia did not differ significantly between the ropivacaine and placebo group (3.8 ± 3 vs 4. 2 ± 2.6, P = .56). The median 12-hour opioid consumption was 11.3mg [2.5–21.5] vs 12.5 mg [5.1–22.4], median time to first opioid use 64 [22–171.5] vs 41 [21.3–89.5] minutes, and mean quality of recovery on day 1: 90. 7 ± 36 vs 102. 8 ± 20.5 and day 3: 108. 3 ± 21.2 vs 112. 5 ± 22.7, for the ropivacaine and placebo group, respectively. At 30 days, the mean NRS was 3. 4 ± 2.4 vs 3. 6 ± 2.5. Opioid use at 30 days occurred in 12 patients (16.2%) of the ropivacaine and in 15 (20.3%) of the placebo group.

CONCLUSIONS::

Bilateral ESPB with ropivacaine did not reduce early postoperative pain or opioid use in patients undergoing lumbar spinal fusion. Its overall benefits in a multimodal analgesic regimen appear limited and application of bilateral ESPB in all patients undergoing lumbar spine surgery is not recommended.

31 Dec 2025·ANNALS OF MEDICINE

Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial

Article

Author: Zhao, Han-xue ; Shan, Xi-sheng ; Chen, Shao-mu ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei

INTRODUCTION:

Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.

PATIENTS AND METHODS:

A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.

DISCUSSION:

Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.

TRIAL REGISTRATION:

Chinese Clinical Trial Register (ChiCTR2400091157).

01 Dec 2025·Health Science Reports

Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study

Article

Author: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael

ABSTRACT:

Background and Aims:

We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.

Methods:

PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.

Results:

In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.

Conclusion:

Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.

News (Medical) associated with Ropivacaine Hydrochloride

12 Mar 2026

·www.biospace.com

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

-- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three director candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Pacira’s Board issued the following statement: The Pacira Board of Directors and management team are committed to serving the best interests of the Company and all its shareholders. In January 2025, we launched our 5x30 strategy, a focused five-pillar plan with clear, measurable objectives we intend to achieve by 2030 to accelerate performance and position us for sustainable long-term value creation. Today, we are pleased to reiterate the significant progress we have made against these goals in just over a year, including: Treated 2.5 million patients with our products in 2025, reinforcing our path to help 3 million patients annually by 2030. Increased EXPAREL® (bupivacaine liposome injectable suspension) year-over-year volume growth to 6.2% in 2025 versus 3.6% in 2024, marking tangible progress toward our goal of double-digit compounded annual topline growth. We further reinforced our 5-year revenue goal with key intellectual property milestones, namely: Secured a favorable volume-limited settlement of our multi-year patent infringement lawsuit. Strengthened our intellectual property estate to 21 Orange-Book listed patents across two families protecting the EXPAREL franchise, a dramatic evolution from the single patent that was previously litigated. Achieved record-high 2025 GAAP and non-GAAP gross margins of 79% and 81%, respectively, and are on track for our goal of a five-percentage point gross margin improvement over a 2024 baseline of 76%. Advanced two promising Phase 2 clinical programs, PCRX-201 (enekinragene inzadenovec), our novel locally administered gene therapy for osteoarthritis (OA), and PCRX-2002, our complementary, ropivacaine-based, long-acting local analgesic for postsurgical pain. We are now entering a data-rich period with key 2026 milestones that include (i) an interim analysis from our Phase 3 study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in shoulder OA, (ii) topline results from our iovera registration study for the treatment of spasticity, and (iii) 52-week data from Part A of our Phase 2 study of PCRX-201 in knee OA. Expanded our commercial reach both inside and outside the U.S. by signing high-caliber commercial collaborations with J&J MedTech and LG Chem. In our regular conversations with Pacira shareholders representing a majority of outstanding shares, we have heard clear support for our growth strategy. With that, we are accelerating our transition into an innovative biopharmaceutical and therapeutic leader in musculoskeletal pain and adjacencies all while advancing a discipline capital allocation strategy that includes (i) driving topline growth by leveraging our established commercial infrastructure; (ii) advancing an innovative pipeline; and (iii) returning capital to shareholders. In 2025, we executed $150 million in common stock repurchases, reducing our outstanding shares from 47 to 41 million. Since Frank Lee became Pacira’s Chief Executive Officer in January of 2024, members of our Board and leadership team have met with DOMA 12 times. DOMA has not provided any new insights regarding our strategy or operations that the Company and the Board are not already carefully evaluating and executing as part of our 5x30 strategy for growth and value creation. The Pacira Board and management team will continue to act in the best interests of the Company and all its shareholders and remain confident that Pacira is well positioned to accelerate growth and continue executing its long-term plan to deliver value. The Board’s Nominating, Governance and Sustainability Committee will carefully review the proposed nominees in due course, consistent with its established processes and corporate governance guidelines. The Board will present its recommendation with respect to the election of directors in the Company’s definitive proxy statement, which will be filed with the U.S. Securities and Exchange Commission and distributed to all shareholders eligible to vote at the 2026 Annual Meeting. The date of the Annual Meeting has not yet been announced, and shareholders are not required to take any action at this time. About Pacira Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera ® °, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee To learn more about Pacira, visit Forward-Looking Statements Any statements in this document about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2026 annual meeting of shareholders; Pacira’s board of directors, the contributions of new directors; ‘5x30’, our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL ® (bupivacaine liposome injectable suspension), ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) and iovera ® °; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec); the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology or our proprietary high-capacity adenovirus (“HCAd”) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential pMVL- or HCAd-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent Pacira’s views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira’s views as of any date subsequent to the date of this document. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira’s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC. Important Additional Information Regarding Proxy Solicitation Pacira intends to proxy statement and BLUE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for Pacira’s 2026 annual meeting of stockholders (the “2026 Proxy Statement,” and such meeting the “2026 Annual Meeting”). BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING PACIRA’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when available for no charge on the SEC’s website at and on Pacira’s investor relations website at Participants in the Solicitation Pacira, its directors, director nominees, certain of its executive officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2026 Annual Meeting. Information regarding the names of Pacira’s directors and executive officers and their respective interests in Pacira by security holdings or otherwise is set forth in Pacira’s proxy statement for the 2025 Annual Meeting of stockholders, filed with the SEC on April 29, 2025 (the “2025 Proxy Statement”). Please refer to the sections captioned “Director Compensation,” “Executive Compensation,” and “Stock Ownership Information” in the 2025 Proxy Statement. To the extent holdings of such participants in Pacira’s securities have changed since the amounts described in the 2025 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC: Form 4, filed by Jonathan Slonin on June 5, 202 5 ; Form 4, filed by Kristen Williams on June 5, 202 5 ; Form 4, filed by Lauren Riker on June 5, 202 5 ; Form 4, filed by Alethia Young on June 13, 202 5 ; Form 4, filed by Michael J. Yang on June 13, 202 5 ; Form 4, filed by Laura Brege on June 1 3 , 202 5 ; Form 4, filed by Christopher Christie on June 13, 202 5 ; Form 4, filed by Mark Froimson on June 13, 202 5 ; Form 4, filed by Marcelo Bigal on June 13, 2025 ; Form 4, filed by Abraham Ceesay on June 13, 202 5 ; Form 4, filed by Mark A. Kronenfeld on June 13, 202 5 ; Form 4, filed by Jonathan Slonin on August 4 , 202 5 ; Form 4, filed by Marcelo Bigal on August 1 1 , 202 5 ; Form 4, filed by Abraham Ceesay on September 8, 2025 , Form 4, filed by Shawn Cross on November 3, 202 5 ; Form 4, filed by Shawn Cross on November 1 3, 202 5 ; Form 4, filed by Jonathan Slonin on November 1 9 , 202 5 ; Form 4, filed by Shawn Cross on December 11, 2025 ; Form 4, filed by Frank Lee on J anuary 6, 2026 ; Form 4, filed by Jonathan Slonin on January 6, 2026 ; Form 4, filed by Brendan Teehan on January 6, 2026 ; Form 4 filed by Lauren Riker on Januar y 6, 2026 ; Form 3, filed by Samit Hirawat on January 29, 2026 ; Form 4, filed by Samit Hirawat on January 2 9, 2026 ; Form 4, filed by Lauren Riker on Feb ruary 3, 2026 ; Form 4, filed by Kristen Williams on February 3, 2026 ; Form 4, filed by Jonathan Slonin on February 3, 2026 ; Form 4, filed by Brendan Teehan on February 3, 2026 ; Form 4, filed by Frank Lee on February 3, 2026 ; Form 4, filed by Kristen Williams on February 13, 2026 ; Form 4, filed by Shawn Cross on February 13, 2026 ; Form 4, filed by Jonathan Slonin on February 13, 2026 ; Form 4, filed by Frank Lee on February 13, 2026 ; Form 4, filed by Brendan Teehan on February 13, 2026 ; Form 4 filed by Lauren Riker on Feb ruary 13, 2026 . Additional information can also be found in Pacira’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 . Details concerning potential participants in the solicitation, including Pacira’s director nominees for election at the 2026 Annual Meeting, will also be included in the 2026 Proxy Statement. These documents, including the definitive 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when available for no charge on the SEC’s website at and on Pacira’s investor relations website at Non-GAAP Financial Information This document contains a financial measure that does not comply with U.S. generally accepted accounting principles (GAAP), non-GAAP gross margin, because this non-GAAP financial measure excludes the impact of items that management believes affect comparability or underlying business trends. This measure supplements Pacira’s financial results prepared in accordance with GAAP. Pacira management uses this measure to better analyze its financial results, estimate its future gross margin and to help make managerial decisions. In management’s opinion, this non-GAAP measure is useful to investors and other users of Pacira’s financial statements by providing greater transparency into the ongoing operating performance of Pacira and its future outlook. Such measure should not be deemed to be an alternative to GAAP requirements. The non-GAAP measure presented here is also unlikely to be comparable with non-GAAP disclosures released by other companies. See the table below for a reconciliation of GAAP gross margin to non-GAAP gross margin. Pacira BioSciences, Inc. Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except percentages) (unaudited) Year Ended December 31, 2025 2024 Gross margin reconciliation: GAAP total revenues $ 726,411 $ 700,966 GAAP gross margin $ 576,662 $ 530,538 GAAP gross margin percentage 79 % 76 % Adjustments to GAAP gross margin: Stock-based compensation $ 6,448 $ 5,331 Decommissioning of manufacturing suite 1 6,521 — Non-GAAP gross margin $ 589,631 $ 535,869 Non-GAAP gross margin percentage 81 % 76 % [1] In July 2025, as a result of improving manufacturing efficiencies for EXPAREL, we announced the decommissioning of our 45-liter EXPAREL batch manufacturing suite located at our Science Center Campus in San Diego, California, and reduced our workforce accordingly. During the year ended December 31, 2025, we recognized $6.5 million of accelerated depreciation expense on fixed assets and reserved raw materials associated with this manufacturing suite that was recorded to cost of goods sold in the consolidated statement of operations. Contacts Investor Contact Susan Mesco (973) 451-4030 susan.mesco@pacira.com Media Contact Sara Marino (973) 370-5430 sara.marino@pacira.com

Phase 2Phase 3

02 Mar 2026

·www.biospace.com

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented real-world evidence from its Innovations in Genicular Outcomes Registry, (IGOR), a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that EXPAREL® (bupivacaine liposome injectable suspension) was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty (TKA) as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with ioveraº was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons (AAOS) 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana. “OA is a unique condition that patients live with for decades and receive a myriad of pain treatments as their disease progresses. The IGOR is providing much-needed real-world evidence and in-depth insights into the patient journey, including the relationship between pain, opioid use, and recovery outcomes,” said Jonathan Slonin, Chief Medical Officer at Pacira. “The data being generated from this first-of-its-kind registry have the potential to meaningfully inform evidence-based preoperative pain management strategies and optimize postoperative recovery outcomes for patients with OA knee pain.” Pacira Presentations at AAOS 2026: “Intraoperative Liposomal Bupivacaine Is Associated With Improved Pain, Opioid Use, Functional, and Length of Stay Outcomes After Total Knee Arthroplasty: Real-world Evidence” (Poster #e0234): Evaluates the real-world effectiveness of liposomal bupivacaine (LB) versus conventional local anesthetics (LAs) in patients undergoing primary total knee arthroplasty (TKA). Data was collected from IGOR for opioid-naive patients who underwent unilateral primary TKA with up to 3 months of follow-up after surgery (LB, n=42; conventional LAs, n=183). The numerical rating scale (NRS) was used to assess acute pain during the first postsurgical week, and the Brief Pain Inventory-Short Form (BPI-SF) was used to assess chronic pain for subsequent time points. The data showed that patients receiving LB demonstrated lower average and worst pain scores (as measured by NRS) than those receiving conventional LAs in the first 5 days (average pain, 3.9 vs 4.9 [ P <0.001]; worst pain, 5.9 vs 7.1 [ P <0.001]) as well as lower average pain scores measured by BPI-SF scores in the subsequent 3 months (2.6 vs 2.9; P =0.03) after TKA. Worst pain scores within the first 5 days were also lower among patients receiving LB compared with those receiving conventional LAs ( P <0.001). Additionally, patients who received LB were also discharged earlier than those receiving conventional LAs (15.0 vs 20.6 h; P=0.007). Presenter : Mary DiGiorgi, Senior Vice President, Clinical Development & Clinical Affairs, Pacira BioSciences Poster Number : e0234 Date & Time : March 2 n d , 2026, 7:00 AM CST “Cryoneurolysis for Knee Osteoarthritis in a Real-World Registry: Pain and Functional Outcomes over 12 Months” (Poster #e0233): Evaluates real-world pain and functional outcomes from the Innovations in Genicular Outcomes Registry (IGOR) following cryoneurolysis therapy for knee osteoarthritis (OA). In this prospective, observational, registry-based real-world study, two cryoneurolysis approaches were evaluated in adult patients with primary knee OA. Data on pain and functional outcomes were collected from IGOR for up to 12 months of follow-up after cryoneurolysis treatment (of 129 patients who received cryoneurolysis, 75 received Cryo-Deep/Both and 54 received Cryo-Superficial). The data presented signifies that treatment with cryoneurolysis in patients with knee OA was associated with long-term reductions in pain and improved function in a real-world setting over 12 months ( P <0.01). Cryoneurolysis was relatively more effective compared with conventional intra-articular (IA) agents, most of which typically provide pain relief and functional improvement for 4-6 months. This data supports the use of cryoneurolysis for long-term pain management in patients with knee OA. Presenter: Mitchell K. Ng, MD Poster Number : e0233 Date & Time : March 2 nd , 2026, 7:00 AM CST About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for OA of the knee. To learn more about Pacira, visit . About EXPAREL® (bupivacaine liposome injectable suspension) EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at Important Safety Information about EXPAREL for Patients EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old, for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder. About iovera ® ° The iovera° system uses the body’s natural response to cold to treat peripheral nerves and immediately reduce pain without the use of drugs. Treated nerves are temporarily stopped from sending pain signals for a period of time, followed by a restoration of function. Treatment with iovera° works by applying targeted cold to a peripheral nerve. A precise cold zone is formed under the skin that is cold enough to immediately prevent the nerve from sending pain signals without causing damage to surrounding structures. The effect on the nerve is temporary, providing pain relief until the nerve regenerates and function is restored. Treatment with iovera° does not include injection of any substance, opioid, or any other drug. The effect is immediate and can last up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. Additional information is available at . Indication and Select Important Safety Information for iovera° Indication: iovera° applies freezing cold to peripheral nerve tissue to block and/or relieve pain for up to 90 days. It should not be used to treat central nervous system tissue. Important Safety Information Do not receive treatment with iovera° if you experience hypersensitivity to cold or have open and/or infected wounds near the treatment site. You may experience bruising, swelling, inflammation and/or redness, local pain and/or tenderness, and altered feeling at the site of application. In treatment area(s), you may experience damage to the skin, skin darkening or lightening, and dimples in the skin. You may experience a temporary loss of your ability to use your muscles normally outside of the treatment area. Talk to your doctor before receiving treatment with iovera°. About IGOR IGOR is a multi-center, multi-treatment, multi-outcome long-term registry that has the potential to provide valuable insights into safety, clinical effectiveness, patient response and economic outcomes of various treatment methods over time in real world practice. These insights can provide valuable information to help guide best practices for current surgical and non-surgical treatments of knee osteoarthritis, as well as inform the development of future therapies by providing a better understanding of patient characteristics and treatment response. Recognizing that osteoarthritis management spans multiple treatment paradigms, the IGOR registry was designed and is being conducted in collaboration with a multi-disciplinary team of specialists in orthopedic surgery, sports medicine, physiatry, rheumatology and family medicine. The robust design of IGOR is intended to capture real-world data across a broad range of osteoarthritis treatments, reflecting each patient’s dynamic care journey over an extended period. The study collects robust patient characteristics, as well as clinical, economic and patient-reported outcomes, with most patients contributing data over several years across multiple interventions. Much of this outcomes data is gathered directly from representative patients and clinical settings, with long-term engagement contributing to high quality, meaningful insights. Forward-Looking Statements Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the contributions of new directors; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology or our proprietary high-capacity adenovirus (“HCAd”) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential pMVL- or HCAd-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC. CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 248-7005 sara.marino@pacira.com

Clinical ResultPhase 2Drug Approval

05 Jan 2026

·www.biospace.com

Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain

Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. - QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hours following infiltration compared to both ropivacaine hydrochloride injection and placebo in both Phase 3 trials. - QP-6211 was generally well tolerated. - Nanjing Delova has submitted a New Drug Application (NDA) for QP-6211. Nanjing, China – December 19, 2025 - Nanjing Delova Biotech Co., Ltd. (“Delova”) today announced positive results from two pivotal Phase 3 clinical trials evaluating QP-6211, a long-acting ropivacaine injection, for the management of postoperative pain following hemorrhoidectomy or bunionectomy surgery. QP-6211 is the first and only long-acting ropivacaine with two positive Phase 3 data demonstrating superior and sustained postoperative pain relief through the critical 72h postoperative period. About QP-6211 for Postoperative Pain QP-6211 is an investigational, novel, extended-released formulation of ropivacaine, designed to provide prolonged postoperative local analgesia via infiltration, and potentially via peripheral nerve block or fascial plane block. Ropivacaine is an amide local anesthetic, which differs from bupivacaine due to its high safety threshold for cardiotoxicity and greater selectivity for blocking A-delta and C pain fibers relative to A-alpha motor fibers. QP-6211 utilizes Delova‘s proprietary Cryslova TM technology platform composed of a dilutable, aqueous (oil-free), injectable suspension containing ropivacaine. Following administration, ropivacaine is released continuously and uniformly for at least 5 days, with consistent pharmacokinetic performance across different surgical models. As a next-generation long-acting local anesthetic, QP-6211 has the potential to become the Best-In-Class non-opioid option for postoperative pain. Phase 3 Efficacy Results in Patients Undergoing Hemorrhoidectomy This pivotal Phase 3 trial was a prospective, randomized, double-blind, placebo- and active-controlled, multicenter clinical trial designed to evaluate the efficacy and safety of single-dose QP-6211 administered via infiltration for postoperative pain control following hemorrhoidectomy in 309 Chinese patients. Primary and Secondary Outcomes in Phase 3 Trial Following Hemorrhoidectomy QP-6211 (N=154) ROP HCl (N=77) Placebo (N=78) Primary: AUC 0-72h of NRS Mean % reduction compared to placebo 58% 10% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- Secondary: AUC 48-72h of NRS Mean % reduction compared to placebo 55% 8% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- Total opioid consumption (0-72h) Mean % reduction compared to placebo 88% 38% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- No-opioid use (0-72h) Proportion of patients 83% 27% 23% Mean difference from placebo 60% 4% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- ROP = ropivacaine; AUC = the area under the curve; NRS = the Numerical Rating Scale pain intensity scores. Results of other secondary endpoints in this Phase 3 trial were generally consistent with those of the primary endpoint. Phase 3 Efficacy Results in Patients Undergoing Bunionectomy This pivotal Phase 3 trial was a prospective, randomized, double-blind, placebo- and active-controlled, multicenter clinical trial designed to evaluate the efficacy and safety of single-dose QP-6211 administered via infiltration for postoperative pain control following bunionectomy in 185 Chinese patients. Primary and Secondary Outcomes in Phase 3 Trial Following Bunionectomy QP-6211 (N=92) ROP HCl (N=46) Placebo (N=47) Primary: AUC 0-72h of NRS Mean % reduction compared to placebo 49% 11% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- Secondary: AUC 48-72h of NRS Mean % reduction compared to placebo 51% 7% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- Total opioid consumption (0-72h) Mean % reduction compared to placebo 74% 26% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- No-opioid use (0-72h) Proportion of patients 75% 26% 23% Mean difference from placebo 52% 3% -- P value vs. placebo <0.0001 -- -- P value vs. ROP HCl <0.0001 -- -- ROP = ropivacaine; AUC = the area under the curve; NRS = the Numerical Rating Scale pain intensity scores. Results of other secondary endpoints in this Phase 3 trial were generally consistent with those of the primary endpoint. Phase 3 Safety Results QP-6211 was generally well tolerated in two Phase 3 studies. The majority of adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to QP-6211. l Hemorrhoidectomy Phase 3 trial: The overall AE incidence in the QP-6211 group was similar to that in the placebo group. AEs reported in ≥5% of patients and more frequently than placebo included dyschezia (9.1% vs. 3.8%), fever (6.5% vs. 5.1%) , constipation (5.8% vs. 3.8%), and diarrhea (5.2% vs. 1.3%). l Bunionectomy Phase 3 trial: The overall AE incidence was lower in the QP-6211 group than in the placebo group, with no AEs occurring in ≥5% of patients at a higher frequency than placebo. About Nanjing Delova Biotech Co., Ltd. Nanjing Delova Biotech Co., Ltd., headquartered in Nanjing, China, is a commercial-stage biotechnology company focused on the development of novel non-opioid analgesics to address unmet medical needs globally. The company is advancing a series of long-acting analgesics based on its proprietary long-acting technology platform, as well as innovative small-molecule therapies. Delova’s first product, QP001 (meloxicam injection), is approved for the management of moderate-to-severe pain in adults and is marketed as QAMZOVA ® in the United States (FDA-approved) and 普坦宁 ® in China (NMPA-approved). Delova has submitted a NDA for QP-6211 to the China NMPA. Investor Relations and Media Contact: Bin Xu BD Director Nanjing Delova Biotech Co., Ltd. xubin@delovabio.com +86 18262593842

Clinical ResultPhase 3Drug ApprovalNDA

100 Deals associated with Ropivacaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04048	Ropivacaine Hydrochloride	N01BB09	DB00296

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Labor Pain	Australia	Medis Pharma Pty Ltd.	27 Feb 2013
Pain, Postoperative	Japan	Sandoz AG	04 Apr 2001
Acute Pain	Austria	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Belgium	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	France	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Germany	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Ireland	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Italy	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Luxembourg	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	Netherlands	Aspen Pharma Trading Ltd.	22 Apr 1996
Acute Pain	United Kingdom	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Austria	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Belgium	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	France	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Germany	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Ireland	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Italy	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Luxembourg	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	Netherlands	Aspen Pharma Trading Ltd.	22 Apr 1996
Anesthesia	United Kingdom	Aspen Pharma Trading Ltd.	22 Apr 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hernia, Inguinal	Phase 3	-	Taiwan Liposome Co., Ltd.	01 Apr 2025
Analgesia	Phase 3	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	21 Mar 2023
Bunion	Phase 3	United States	PRF Technologies Ltd.	13 Mar 2023
Hallux Valgus	Phase 2	United States	Taiwan Liposome Co., Ltd.	05 Mar 2019
Pain	Clinical	France	AstraZeneca PLC	01 Mar 2009
Neurolytic Block	Preclinical	Taiwan Province	Taiwan Liposome Co., Ltd.	01 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05345249 (Pubmed \| Anesth Analg)	Phase 4	Pain, Postoperative	76	Bilateral ESPB with ropivacaine	mnjwbjsqyh(deruuxcrtx) = gqwpqmgbmq dajrrshcrt (lieabusevg, 3.0) View more	Negative	01 Mar 2026
				Placebo (normal saline)	vfmkjedogi(qekwlihtxp) = mapskfwhrw agpricidkw (lywpsnfnie ) View more
NCT05488847 (CTgov)	Phase 4	Shoulder Pain \| Periarthritis scapulohumeralis	83	pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol)	mbsnejqtym(nifdvbltue) = fqhtdxeyvd kyehzpmeil (xqkbdhgmpf, 1.7)	-	10 Feb 2026
				pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol)	mbsnejqtym(nifdvbltue) = ptambbxhhv kyehzpmeil (xqkbdhgmpf, 1.6) View more
NCT05279898 (PATHFINDERII, CTgov)	Not Applicable	Cognitive Dysfunction \| Pain \| Emergence Delirium	70	dexmedetomidine+EEG Monitoring+Ropivacaine+Propofol+Rocuronium+Ketamine+Remifentanil (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided)	gbndgmuias(jolydiyhmu) = ykxkxuufgo iboyiweyzy (ipnanvkpxs, 28.5) View more	-	26 Nov 2025
				Dexmedetomidine+fentanyl+Hydromorphone+Acetaminophen+Oxycodone+Propofol+Sevoflurane+Lidocaine (Standard of Care/Control)	gbndgmuias(jolydiyhmu) = eizefcucxb iboyiweyzy (ipnanvkpxs, 79.9) View more
NCT05054179 (Pubmed \| Reg Anesth Pain Med)	Phase 3	-	80	Ropivacaine 0.2%	qxdixlhpvy(nttuvosrbg) = vgcrwwvnse thtbvqzcqw (yapquzblwd, 2.2) View more	Negative	05 Nov 2025
				Normal saline	qxdixlhpvy(nttuvosrbg) = tffkevtstk thtbvqzcqw (yapquzblwd, 2.2)
NCT05190120 (CTgov)	Phase 4	Pain \| Lacerations \| Anterior Cruciate Ligament Injuries	132	ropivacaine (Femoral Block for Knee Arthroscopy/Meniscus Surgery)	bgeyiznfbp(ctdrnmihep) = iobygvyyld qsvktzbuud (xycajcynpj, kodhkvggqy - ajetzfbcfv) View more	-	30 Sep 2025
				ropivacaine (Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery)	bgeyiznfbp(ctdrnmihep) = gmxnlhwdga qsvktzbuud (xycajcynpj, ymgqtplkwt - tnvcyjlyon) View more
NCT00210132 (ROPAL-1, CTgov)	Phase 2	Second Primary Neoplasms \| Neoplasms \| Pain, Postoperative	90	Ropivacaine (Ropivacaine Arm)	oapauqnxpf = uxsuqdhfmh svujnpyodh (jaehzscdbw, hahjuhxqvf - vsiosldyvj) View more	-	08 Sep 2025
				Reference (Reference Arm)	oapauqnxpf = xwhfbikdjr svujnpyodh (jaehzscdbw, bvniaesdhw - eqoohkmcpi) View more
NCT05688670 (CTgov)	Phase 4	Heart Septal Defects, Atrial \| Pain, Procedural \| Heart Septal Defects, Ventricular	52	Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia)	qirsfyrlvn(ffksdvastv) = ifjfmwllfg rycdfjncqy (luhjtuguzc, 0.19) View more	-	28 Aug 2025
				Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration)	qirsfyrlvn(ffksdvastv) = gyeirswjvi rycdfjncqy (luhjtuguzc, 0.39) View more
NCT04588389 (CTgov)	Phase 3	Pain \| Intervertebral Disc Disease	9	Ropivacaine+lidocaine (Group 1 Standard of Care)	bnosdvfqij(tljoynuesc) = kaosffavph pzgsshvmta (rfsrtsjagb, nusqnexftv - ovmgxeldfc) View more	-	28 Jul 2025
				Ropivacaine+lidocaine (Group 2 Standard of Care + Quadratus Lumborum Block II)	xlltvisbif(heyyvxwemg) = gjsapcqxzf nhwgxdbsbf (pqndjbmerr, tsueoqpvbl - avhlbhtlnv) View more
Pubmed \| J Hand Surg Am	Not Applicable	Analgesia	91	Lidocaine	jptzqfaglq(mjbnacprid) = kwdkhyvhtz phjijgpmqq (ejkvkibyyz, 4 - 12) View more	Negative	01 Jul 2025
				Lidocaine + Ropivacaine	jptzqfaglq(mjbnacprid) = goqbwfohxn phjijgpmqq (ejkvkibyyz, 4 - 10) View more
NCT05023343 (Pubmed \| Reg Anesth Pain Med)	Phase 4	Muscle Weakness	20	Unilateral anterior quadratus lumborum block with 30 mL ropivacaine 0.75%	kkvsiwlouc(gedeghkvnz) = fnzvdlaodk xtrqdlboww (mrhbalzobn, -0.38 to -0.08) View more	Positive	01 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis